Belén Garijo, Merck KGaA CEO (Arne Dedert/picture alliance via Getty Images)
June 24, 2024 03:41 PM EDT
R&D

Mer­ck KGaA's bet on head and neck can­cer drug from De­bio­pharm ends in Phase 3 fail­ure

Drew Armstrong

Executive Editor

Mer­ck KGaA’s Phase 3 tri­als of xev­ina­pant, the can­cer drug it li­censed from De­bio­pharm in 2021, are wind­ing down af­ter the drug showed that it …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

Cal­tech spin­out de­buts with AI-dri­ven 'mir­ror pep­tide' plat­form

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times